NO20070585L - Humane anti-KIR antistoff. - Google Patents

Humane anti-KIR antistoff.

Info

Publication number
NO20070585L
NO20070585L NO20070585A NO20070585A NO20070585L NO 20070585 L NO20070585 L NO 20070585L NO 20070585 A NO20070585 A NO 20070585A NO 20070585 A NO20070585 A NO 20070585A NO 20070585 L NO20070585 L NO 20070585L
Authority
NO
Norway
Prior art keywords
antibody
natural killer
subjects
cytotoxicity
derivatives
Prior art date
Application number
NO20070585A
Other languages
English (en)
Other versions
NO341198B1 (no
Inventor
Ivan Svendsen
Francois Romagne
Soren Berg Padkjaer
Alessandro Moretta
Mariella Della Chiesa
Pascale Andre
Laurent Gauthier
Peter Andreas Nicolai Remert Wagtmann
Matthias Thorolfsson
Anders Svensson
Stefan Zahn
Pieter Spee
Kristian Kjaergaard
Michael Wilken
Original Assignee
Innate Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/002464 external-priority patent/WO2005003172A2/en
Priority claimed from PCT/EP2005/053122 external-priority patent/WO2006003179A2/en
Application filed by Innate Pharma Sas filed Critical Innate Pharma Sas
Publication of NO20070585L publication Critical patent/NO20070585L/no
Publication of NO341198B1 publication Critical patent/NO341198B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B7/00—Special arrangements or measures in connection with doors or windows
    • E06B7/02—Special arrangements or measures in connection with doors or windows for providing ventilation, e.g. through double windows; Arrangement of ventilation roses
    • E06B7/08—Louvre doors, windows or grilles
    • E06B7/084—Louvre doors, windows or grilles with rotatable lamellae
    • E06B7/086—Louvre doors, windows or grilles with rotatable lamellae interconnected for concurrent movement
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0615—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the closing elements
    • E06B9/0638—Slats or panels
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0646—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position
    • E06B9/0653—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position stored side by side in the closing plane
    • E06B9/0661—Lazy tongue, pantograph or scissor-like systems in the plane of the opening
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/24—Screens or other constructions affording protection against light, especially against sunshine; Similar screens for privacy or appearance; Slat blinds
    • E06B9/26—Lamellar or like blinds, e.g. venetian blinds
    • E06B9/28—Lamellar or like blinds, e.g. venetian blinds with horizontal lamellae, e.g. non-liftable
    • E06B9/30—Lamellar or like blinds, e.g. venetian blinds with horizontal lamellae, e.g. non-liftable liftable
    • E06B9/302—Lamellar or like blinds, e.g. venetian blinds with horizontal lamellae, e.g. non-liftable liftable without ladder-tape, e.g. with lazy-tongs, with screw spindle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0646—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position
    • E06B9/0653—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position stored side by side in the closing plane
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0646—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position
    • E06B9/0676—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position stored in a stacked configuration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Civil Engineering (AREA)
  • Architecture (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Blinds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SAMMENDRAG Det er beskrevet sammensetninger og fremgangsmåter for å regulere en immunrespons i en pasient. Mer spesielt er det beskrevet humane antistoffer som regulerer aktiviteten til NK-celler og muliggjør en forsterkning av NK-cellecytotoksitet i pattedyrpasienter og antistoffer med antigenbindende egenskaper som er lik de for det humane monoklonale antistoffet 1-7F9 eller 1-4F I. Det er også beskrevet fragmenter og derivater av slike antistoffer så vel som farmasøytiske sammensetninger som omfatter samme og deres anvendelser, da spesielt for bruk i terapi, for å øke eller forsterke NK-celleaktivitet eller cytotoksitet i pasienter.
NO20070585A 2004-07-01 2007-01-31 Humane anti-KIR antistoff. NO341198B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2004/002464 WO2005003172A2 (en) 2003-07-02 2004-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
PCT/DK2004/000470 WO2005003168A2 (en) 2003-07-02 2004-07-01 Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
DKPA200500025 2005-01-06
PCT/EP2005/053122 WO2006003179A2 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use

Publications (2)

Publication Number Publication Date
NO20070585L true NO20070585L (no) 2007-01-31
NO341198B1 NO341198B1 (no) 2017-09-11

Family

ID=38462469

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20070585A NO341198B1 (no) 2004-07-01 2007-01-31 Humane anti-KIR antistoff.
NO20171133A NO344566B1 (no) 2004-07-01 2017-07-07 Isolert antistoff eller fragment derav, nukleinsyre som koder for nevnte antistoff eller antistoffragment, vektor som omfatter nukleinsyren, celle som omfatter vektoren eller hybridom som uttrykker antistoffet eller antistoffragmentet, fremgangsmåte for fremstilling av antistoff eller antistoffragment, farmasøytisk sammensetning omfattende nevnte antistoff eller antistoffragment samt fremgangsmåte for fremstilling av antistoff.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20171133A NO344566B1 (no) 2004-07-01 2017-07-07 Isolert antistoff eller fragment derav, nukleinsyre som koder for nevnte antistoff eller antistoffragment, vektor som omfatter nukleinsyren, celle som omfatter vektoren eller hybridom som uttrykker antistoffet eller antistoffragmentet, fremgangsmåte for fremstilling av antistoff eller antistoffragment, farmasøytisk sammensetning omfattende nevnte antistoff eller antistoffragment samt fremgangsmåte for fremstilling av antistoff.

Country Status (19)

Country Link
EP (1) EP1841941A1 (no)
JP (1) JP5770142B2 (no)
KR (1) KR101299167B1 (no)
CN (1) CN103509111A (no)
AT (1) ATE499386T1 (no)
BR (1) BRPI0512911B1 (no)
CY (1) CY1122391T1 (no)
DE (1) DE602005026538D1 (no)
DK (1) DK1791868T3 (no)
ES (2) ES2360467T3 (no)
HU (1) HUE045639T2 (no)
IL (1) IL179635A0 (no)
LT (1) LT2287195T (no)
MX (1) MX2007000210A (no)
NO (2) NO341198B1 (no)
PT (2) PT2287195T (no)
RU (1) RU2410396C2 (no)
TW (2) TWI472338B (no)
ZA (1) ZA200700736B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3579879A4 (en) * 2017-02-09 2020-12-16 Memorial Sloan Kettering Cancer Center ANTI-BODY ANTI-KIR3DL1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125130B1 (de) * 1998-10-29 2006-07-26 DakoCytomation Denmark A/S Nachweis von säure-resistenten mikroorganismen im stuhl
KR101325023B1 (ko) * 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
DK2287195T3 (da) * 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi

Also Published As

Publication number Publication date
IL179635A0 (en) 2007-05-15
BRPI0512911A (pt) 2008-04-15
KR101299167B1 (ko) 2013-08-30
RU2006144820A (ru) 2008-09-10
BRPI0512911B1 (pt) 2023-05-16
PT1791868E (pt) 2011-05-02
MX2007000210A (es) 2007-08-02
NO341198B1 (no) 2017-09-11
CN103509111A (zh) 2014-01-15
JP5770142B2 (ja) 2015-08-26
JP2013009676A (ja) 2013-01-17
DK1791868T3 (da) 2011-05-16
ES2738578T3 (es) 2020-01-23
RU2410396C2 (ru) 2011-01-27
ATE499386T1 (de) 2011-03-15
KR20070034568A (ko) 2007-03-28
TWI472338B (zh) 2015-02-11
EP1841941A1 (en) 2007-10-10
TWI422389B (zh) 2014-01-11
DE602005026538D1 (de) 2011-04-07
HUE045639T2 (hu) 2020-01-28
TW200612986A (en) 2006-05-01
NO20171133A1 (no) 2007-01-31
ZA200700736B (en) 2008-04-30
NO344566B1 (no) 2020-02-03
CY1122391T1 (el) 2021-01-27
ES2360467T3 (es) 2011-06-06
LT2287195T (lt) 2019-07-25
TW201235048A (en) 2012-09-01
PT2287195T (pt) 2019-07-29

Similar Documents

Publication Publication Date Title
WO2006003179A3 (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2012112544A3 (en) Humanized m-csf mice
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
TW200732347A (en) VEGF analogs and methods of use
MY163480A (en) Sclerostin binding agents
BR112022013756A2 (pt) Anticorpos anti-trem2 e métodos de uso dos mesmos
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
WO2006076240A3 (en) Compositions, products and methods for controlling weight in a mammal
BRPI0514124A (pt) anticorpos monoclonais humanos contra a il-4 humana
WO2007116404A3 (en) Cucurbitacin glucosides and use thereof in treating cancer
EA202192294A1 (ru) Антитела к trem2 и способы их применения
WO2007136910A3 (en) Eimmunotherapy for immune suppressed patients
BR112013031943A2 (pt) "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos".
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
ATE402740T1 (de) Kosmetische zusammensetzungen
CY1122391T1 (el) Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
Kim A taxonomic review of the sword-tailed cricket subfamily Trigonidiinae (Orthoptera: Ensifera: Gryllidae) from Korea
TH92681A (th) สารองค์ประกอบเภสัชภัณฑ์สารปฏิปักษ์แอนติบอดีชนิดต้าน cd40
CY1116013T1 (el) Καταστολη ογκων χρησιμοποιωντας ανθρωπινο πλακουντιακο εκχυμα και ανθρωπινα ενδιαμεσα φυσικα φονικα κυτταρα πλακουντιακης προελευσης